| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: VITX |
| Security Type |
Common Stock |
| Lead Underwriter |
Cowen |
| Days In Registration |
104 |
| Date Filed |
26-Feb-1998 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Develop and manufacture products to eliminate pathogens, such as HIV and Hepatitis B, from transfusion plasma |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
11.94M |
| President and CEO |
John R. Barr |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
3.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
3.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
450.0K |
| File Amount |
$42.0M |
| File Price Range |
$15.00 - $13.00 |
| File Mid Price |
$14.00 |
Current Filing Information
(Amended 5-Jun-1998) |
|
US |
|
Shares Filed |
3.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
3.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$42.0M |
| · % Change from Original |
0.0 |
| File Price Range |
$15.00 - $13.00 |
| File Mid Price |
$14.00 |
|
